Passage Bio
PASG
43 hedge funds and large institutions have $32M invested in Passage Bio in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.36% less ownership
Funds ownership: 3.62% → 3.27% (-0.36%)
10% less funds holding
Funds holding: 48 → 43 (-5)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
41% less capital invested
Capital invested by funds: $54.4M → $32M (-$22.4M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
Top Sellers
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$1.14M |
| 2 |
Two Sigma Advisers
New York
|
-$283K |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$191K |
| 4 |
Millennium Management
New York
|
-$140K |
| 5 |
BlackRock
New York
|
-$128K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| – | -$293 | -11 | Closed |
|
|
FDCDDQ
52
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$14 | -1 | Closed |
|
PASG Hedge Fund Activity: Q2 2024 in Review
43 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2024, worth a combined $32M — down 41% from $54.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PASG and 4 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Vestal Point Capital, adding an estimated $1.9M. The largest seller was Versant Venture Management, cutting an estimated $1.14M.
- 43 institutional investors held Passage Bio (PASG) as of Q2 2024, down from 48 in Q1 2024.
- Funds reported $32M of Passage Bio stock for Q2 2024, down 41% quarter-over-quarter.
- 4 funds opened new Passage Bio positions in Q2 2024 and 9 closed out, a net change of -5 holders.
- The largest Passage Bio buyer in Q2 2024 was Vestal Point Capital, an estimated $1.9M added.
- The largest Passage Bio seller in Q2 2024 was Versant Venture Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2024.